The research, published in Annals of Hematology, took a direct approach to a question that has lingered at the edge of AML biology for years. Rather than inferring apoptotic behavior from broad molecular signatures, the team prospectively measured messenger RNA expression of apoptosis-related genes in bone marrow mononuclear cells from 90 patients with newly diagnosed AML. Every sample came from patients at the start of their treatment journey, before therapy could reshape the transcriptional landscape of their leukemia. That design choice matters, because it allowed the investigators to ask whether the apoptotic wiring present at diagnosis could predict what happened next — how long patients lived, how they responded to treatment, and whether their disease returned.

When the researchers clustered patients according to their apoptosis gene expression profiles, two biologically distinct groups emerged, and the differences between them were striking. The first cluster carried a transcriptional pattern that, on its surface, looked almost reassuring: relatively higher expression of the classic anti-apoptotic gene BCL2, the very gene targeted by one of modern hematology’s most celebrated drugs. The second cluster told a more complicated story. These patients showed coordinated upregulation of a battery of pro-apoptotic genes, including BCL2L11 (better known as BIM), BBC3 (PUMA), BID, BAD, BIK, and BAX — genes whose protein products are supposed to push cells toward self-destruction. At the same time, the cells appeared to shift their survival strategy away from BCL2 and toward alternative anti-apoptotic regulators, with increased expression of MCL1 and BCL2L1, which encodes the survival protein BCL-xL.

That combination — more pro-death genes, but a survival apparatus rebuilt around different guardians — might seem paradoxical, and the clinical outcomes made the paradox impossible to ignore. Patients in the second cluster had significantly inferior overall survival. The researchers also observed reduced expression of CASP3 and CASP7, the executioner caspases that carry out the final, irreversible steps of apoptosis, in this high-risk group. Lower levels of these molecular executioners, the authors suggest, may mean that even when the death signal is triggered, the cell’s machinery for completing the process runs less efficiently. In other words, the leukemic cells of Cluster 2 patients appeared to be shouting the commands for self-destruction while simultaneously dismantling the equipment needed to obey them.

The timing of the study gives its findings particular weight. The treatment of AML has been transformed in recent years by venetoclax, a BCL2 inhibitor that, when combined with the hypomethylating agent azacitidine — a regimen known as VenAza — has become a backbone of therapy for older patients and those unfit for intensive chemotherapy. Venetoclax works by neutralizing BCL2, removing one of the main shields that leukemic cells use to resist apoptosis. If a patient’s leukemia depends heavily on BCL2, the drug should work well. If the cells have quietly reorganized their survival machinery around MCL1 or BCL-xL, the drug’s leverage diminishes. The Lodz team’s data fit that logic with unsettling precision: among patients treated with venetoclax plus azacitidine, those in Cluster 2 demonstrated significantly shorter event-free survival.

The biological features of Cluster 2 help explain why. The researchers noted that this subgroup displayed a monocytic immunophenotype, a characteristic that previous studies had already associated with reduced sensitivity to BCL2-targeted therapy. Monocytic AML cells tend to rely more on MCL1 and other alternative survival proteins than on BCL2 itself, making venetoclax a less effective key for that particular lock. Combined with the transcriptional evidence of increased MCL1 and BCL-xL expression and diminished executioner caspase activity, the picture that emerges is of a leukemia subtype that is not merely more aggressive, but differently engineered — one whose apoptotic architecture is fundamentally less vulnerable to the therapies now widely deployed against it.

Then comes the study’s most provocative single finding. When the researchers examined individual genes rather than cluster-level patterns, one stood out: BIK. Higher BIK mRNA expression was associated with poorer survival and with a lack of response to venetoclax-azacitidine therapy, and the association held up as an independent prognostic marker. The paradox here is sharp. BIK is a pro-apoptotic gene, a member of the BH3-only family whose role is to help tip cells into death. Higher expression of a death-promoting gene should, intuitively, be good news. Instead, in this cohort, it flagged the patients most likely to fare badly. The authors highlight this paradoxical association explicitly, and it serves as a reminder that gene expression in cancer rarely obeys simple intuition — context, coordination, and the surrounding molecular machinery determine whether a signal means surrender or defiance.

Why might high BIK expression accompany worse outcomes? The study’s cluster-level data suggest a plausible framework. In Cluster 2, BIK is upregulated alongside a host of other pro-apoptotic genes as part of a broader transcriptional state, one in which the cell simultaneously bolsters alternative survival pathways through MCL1 and BCL-xL and dampens the caspase machinery that would finalize apoptosis. In that setting, elevated BIK may be less a weapon than a distress signal — a marker of a cellular state in which death pathways are chronically activated yet chronically thwarted. Cells locked in such a standoff may be under persistent stress, and stress-adapted leukemic cells are often the most difficult to eradicate. BIK expression, on this reading, is not causing the poor prognosis but faithfully reporting it, which is precisely what a good biomarker should do.

The clinical implications ripple outward in several directions. First, the study demonstrates that apoptosis-related gene expression, measured at diagnosis, defines clinically distinct AML subgroups — a finding that could eventually inform how patients are risk-stratified beyond the current arsenal of cytogenetic and mutation-based markers. Second, the link between Cluster 2 biology and shortened event-free survival on venetoclax-azacitidine raises the possibility that expression profiling of apoptotic genes could help identify, upfront, which patients are unlikely to benefit from the regimen and might be better served by alternative or combination strategies, including agents targeting MCL1 that are currently in development. Third, the independent prognostic value of BIK offers a concrete, testable candidate for prospective validation in larger and more diverse cohorts.

Cautious interpretation remains essential. The cohort comprised 90 patients treated at a single center, and the findings, while internally coherent, will need replication before they reshape clinical practice. The authors themselves frame the results as demonstrating that dysregulation of apoptosis-related gene expression defines clinically distinct subgroups and may contribute to differences in prognosis and therapeutic response — a claim about mechanism and association rather than a prescription for immediate changes in care. Yet the conceptual shift the study proposes is substantial. AML has traditionally been classified by the mutations its cells carry; this work argues that how those cells manage life and death — the balance of pro- and anti-apoptotic forces, the choice of survival protein, the integrity of the caspase execution machinery — is itself a meaningful axis of disease biology. If subsequent studies confirm the pattern, the humble measurement of apoptosis gene mRNA could become a routine part of the diagnostic conversation, and the paradoxical signal from BIK could stand as a symbol of how much remains to be learned about why some leukemias die on command and others simply will not.

Subject of Research: Apoptosis-related gene expression profiling in acute myeloid leukemia and its association with patient clustering, prognosis, and response to venetoclax-based therapy

Article Title: Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker

Article References: Strzałka, K., Strzałka, P., Jarych, D., Wiśnik, A., Mikulski, D., Kościelny, K., Czemerska, M., Zawlik, I., Wierzbowska, A., & Pluta, A. (2026). Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker. Annals of Hematology. https://doi.org/10.1007/s00277-026-07268-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07268-7

Keywords: acute myeloid leukemia, apoptosis, gene expression profiling, BIK, venetoclax, azacitidine, BCL2, MCL1, prognostic marker, drug resistance, caspases, hematology

At the forefront of these innovations are hypomethylating agents (HMAs) combined with venetoclax (VEN) or with IDH inhibitors, either as dual or triplet therapies. Although frontline treatments may involve either HMA + VEN or HMA + IDH-inhibitors, emerging clinical questions press strongly on the comparative efficacy of AZA + VEN versus AZA + IDH-inhibitors versus the triplet HMA + IDH-inhibitor + VEN regimen. Understanding the sequencing and optimal combination of these agents for maximal patient benefit, especially for those with IDH1/2 mutations, remains a high priority, with current trials like the DATA-I (NCT05401097) actively recruiting to elucidate this clinical conundrum.

At the molecular core of these strategies lies the role of IDH mutations in aberrant epigenetic regulation. Wild-type IDH catalyzes the normal conversion of isocitrate to alfa-ketoglutarate (α-KG), vital for DNA methylation homeostasis. However, mutant IDH enzymes aberrantly generate 2-hydroxy-glutarate (2-HG), a potent oncometabolite that disrupts normal epigenetic marks, causing DNA hypermethylation and subsequent blockade of myeloid cell differentiation. Therapeutic inhibition of mutant IDH restores physiological methylation patterns, thereby alleviating differentiation arrest and promoting leukemic cell maturation.

Building upon this mechanistic insight, triplet regimens that incorporate venetoclax, hypomethylating agents, and IDH inhibitors synergistically induce DNA hypomethylation, normalize methylation patterns, and simultaneously trigger apoptotic pathways. This multi-pronged attack not only counters leukemic cell survival but also reverts the epigenetic landscape to a state conducive to normal differentiation and immune recognition, marking a sophisticated evolution in targeted therapy.

Pioneering clinical evidence emerged from the phase 1/2 trial NCT03471260, which evaluated the triplet of ivosidenib (an IDH1 inhibitor), venetoclax, and azacitidine in newly diagnosed AML patients. This combination demonstrated an encouraging trend toward improved progression-free survival (PFS), with median PFS not reached compared to 11 months in control groups. Although differences in measurable residual disease (MRD)-negative complete remission (CR) rates and overall survival (OS) did not achieve statistical significance, patterns in molecular clearance rates—such as 86% IDH1 clearance—indicate meaningful clinical benefits. Importantly, findings suggest that MRD assessment at later treatment cycles might better predict long-term outcomes, a revelation that could refine monitoring paradigms.

The complexity of AML mutational landscapes further complicates therapeutic response, as mutations in FLT3-TKD, RAS pathways (N/KRAS), NF1, PTPN11, JAK/STAT, KIT, and CSF3R genes correlate with inferior prognosis. Notwithstanding these challenges, the incremental improvement in MRD-negativity rates with successive treatment cycles underscores the dynamic therapeutic window these regimens offer. Future investigations will be critical to delineate how such co-mutations influence treatment stratification and resistance mechanisms.

Enasidenib, targeting mutant IDH2, adds another compelling dimension when combined with venetoclax. A phase study (NCT04092179) conducted on relapsed/refractory (R/R) AML patients revealed an overall response rate (ORR) of 70%, with median OS reaching 9.4 months. Notably, patients carrying the R172 IDH2 mutation fared better than those with the R140 variant, exhibiting ORRs of 83% versus 55%, respectively. These insights into mutation-specific efficacy may soon guide individualized therapeutic decision-making, maximizing benefit and mitigating unnecessary toxicity.

Moving toward wholly oral regimens, trials such as NCT04774393 combine ASTX727 (oral hypomethylating agents) with venetoclax and IDH inhibitors like ivosidenib or enasidenib in patients unfit for intensive chemotherapy. Early results herald impressive efficacy, with MRD-negativity rates reaching 91% in newly diagnosed and 67% in relapsed/refractory subgroups by flow cytometry metrics. Such advances promise enhanced patient convenience, improved adherence, and potentially better quality of life during prolonged AML management.

Comparative analyses pooling data from triplets involving ivosidenib + VEN + AZA versus all-oral triplets reveal comparable outcomes and safety profiles, suggesting oral regimens could indeed supplant injectable therapies without compromising efficacy. This evolution could be especially transformative for elderly or frail patients, for whom hospital visits and parenteral administration pose significant barriers.

Looking ahead, next-generation IDH inhibitors, both selective and dual-targeting agents like olutasidenib and crelosidenib, are under active investigation in phase 1/2 trials (NCT06445959 and NCT04603001) for relapsed/refractory IDH-mutated AML patients ineligible for intensive chemotherapy. These novel agents may offer enhanced potency, improved tolerability, and broader mutation coverage, expanding the therapeutic arsenal against this aggressive malignancy.

The real promise of combining venetoclax with epigenetic modifiers and IDH inhibitors lies in its ability to induce durable remissions without relying on traditional cytotoxic chemotherapy’s toxic side effects. By exploiting vulnerabilities in the leukemic epigenome and apoptotic machinery, clinicians aspire to convert AML into a manageable chronic condition with long-lasting remission periods and minimal collateral damage.

Moreover, MRD negativity, increasingly recognized as a surrogate marker for durable responses, gains renewed significance in the context of these targeted regimens. The observation that delayed MRD negativity does not equate to poor outcomes suggests rethinking MRD kinetics and timing to enhance prognostic accuracy and inform therapeutic adjustments.

The intricate interplay of mutational profiles influencing response, resistance, and relapse risk underscores the necessity of comprehensive molecular profiling before treatment initiation. Precision medicine in AML, informed by deep genomic insights, stands at the cusp of delivering truly individualized, chemotherapy-free regimens that optimize efficacy while minimizing toxicity.

In summary, chemotherapy-free combinations incorporating venetoclax and targeted agents represent a vibrant frontier in AML therapy, particularly for vulnerable elderly or unfit populations with IDH mutations. While promising early-phase results signal improved survival and remission durability, ongoing randomized trials and extended follow-up are essential to conclusively establish these combinations as new standard-of-care options. The collaborative synergy of epigenetic modulation, apoptotic priming, and metabolic normalization foretells a paradigm shift that may very well redefine AML management in the coming years.

The rapid accrual of evidence supporting oral formulations further bolsters the case for outpatient, patient-centric care models, reducing healthcare burden while maintaining or enhancing clinical outcomes. As new IDH inhibitors advance through clinical development, they will potentially complement or supplant existing options, deepening therapeutic impact.

Ultimately, the comprehensive approach targeting epigenetic dysregulation, metabolic anomalies, and apoptotic pathways paves the way for sustained remission and improved quality of life in acute myeloid leukemia, offering hope to patients previously facing limited options. The oncology community eagerly anticipates results from ongoing and future trials that will refine and solidify this chemotherapy-free revolution.

Subject of Research:
Chemotherapy-free management strategies for acute myeloid leukemia (AML) using venetoclax in combination with targeted epigenetic and immune therapies, focusing on IDH-mutated patients unfit for intensive chemotherapy.

Article Title:
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.

Article References:
Kegyes, D., Tat, A., Vizitiu, A.S. et al. Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies. Cell Death Discov. 11, 379 (2025). https://doi.org/10.1038/s41420-025-02678-4

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02678-4